Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15,006Revenue $M4,464Net Margin (%)7.5Z-Score3.8
Enterprise Value $M16,227EPS $2.0Operating Margin %10.9F-Score7
P/E(ttm))45.2Cash Flow Per Share $4.7Pre-tax Margin (%)8.9Higher ROA y-yY
Price/Book4.410-y EBITDA Growth Rate %-7.0Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %-24.8Current Ratio2.4Lower Leverage y-yY
Price/Cash Flow6.8y-y EBITDA Growth Rate %270ROA % (ttm)5.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M169ROI % (ttm)-1.9Gross Margin Increase y-yY

Gurus Latest Trades with HSP

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSPMario Gabelli 2014-12-31 Add0.03%$48.12 - $62.84
($56.51)
$ 87.7155%Add 38.25%352,370
HSPJoel Greenblatt 2014-12-31 Sold Out -0.16%$48.12 - $62.84
($56.62)
$ 87.7155%Sold Out0
HSPJoel Greenblatt 2014-09-30 Buy 0.16%$49.59 - $56.21
($53.12)
$ 87.7165%New holding, 313242 sh.313,242
HSPMario Gabelli 2014-09-30 Add0.01%$49.59 - $56.21
($53.12)
$ 87.7165%Add 24.71%254,870
HSPJohn Rogers 2014-09-30 Reduce-0.45%$49.59 - $56.21
($53.12)
$ 87.7165%Reduce -22.28%2,433,369
HSPMario Gabelli 2014-06-30 Add0.01%$42.14 - $52.41
($47.4)
$ 87.7185%Add 32.91%204,370
HSPJohn Rogers 2014-06-30 Reduce-0.53%$42.14 - $52.41
($47.4)
$ 87.7185%Reduce -24.15%3,130,809
HSPVanguard Health Care Fund 2014-03-31 Add0.18%$40.89 - $45
($42.83)
$ 87.71105%Add 22.69%8,375,170
HSPMario Gabelli 2014-03-31 Add0.01%$40.89 - $45
($42.84)
$ 87.71105%Add 30.68%153,770
HSPRichard Snow 2014-03-31 Sold Out -1.3%$40.89 - $45
($42.84)
$ 87.71105%Sold Out0
HSPBrian Rogers 2014-03-31 Sold Out -0.37%$40.89 - $45
($42.84)
$ 87.71105%Sold Out0
HSPJohn Rogers 2014-03-31 Reduce-0.28%$40.89 - $45
($42.84)
$ 87.71105%Reduce -11.62%4,127,850
HSPJohn Rogers 2013-12-31 Add0.12%$38.53 - $42.19
($40.25)
$ 87.71118%Add 5.28%4,670,630
HSPRichard Snow 2013-09-30 Reduce-0.85%$38.45 - $42.03
($39.88)
$ 87.71120%Reduce -36.89%811,590
HSPRichard Pzena 2013-09-30 Sold Out -0.27%$38.45 - $42.03
($39.88)
$ 87.71120%Sold Out0
HSPJohn Rogers 2013-09-30 Reduce-0.23%$38.45 - $42.03
($39.88)
$ 87.71120%Reduce -7.79%4,436,305
HSPJohn Rogers 2013-06-30 Add0.34%$30.57 - $38.31
($33.81)
$ 87.71159%Add 12.97%4,811,105
HSPBrian Rogers 2013-06-30 Add0.24%$30.57 - $38.31
($33.81)
$ 87.71159%Add 135.3%2,750,000
HSPRichard Snow 2013-06-30 Reduce-0.27%$30.57 - $38.31
($33.81)
$ 87.71159%Reduce -11.68%1,286,067
HSPMichael Price 2013-03-31 Add0.65%$28.96 - $35.99
($32.42)
$ 87.71170%Add 61.62%400,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HSP Mario Gabelli 2014-12-31352,3700.210.11+38.25%
HSP Michael Price 2014-12-31400,0000.243
HSP Robert Bruce 2014-12-3110,0000.010.17
HSP Vanguard Health Care Fund 2014-12-317,966,9704.711.1-4.87%
HSP John Rogers 2014-12-312,311,3091.371.6-5.02%
HSP Joel Greenblatt 2014-12-31000Sold Out
HSP Meridian Funds 2013-06-30257,4000.150.37+8.42%
Premium Most recent portfolio changes are included for Premium Members only!


HSP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Werner Thomas ESVP, Finance & CFO 2015-02-17Sell1,566$87.350.24view
Werner Thomas ESVP, Finance & CFO 2015-01-15Sell10,000$61.5642.24view
Stober Matthew RSVP, Operations 2015-01-12Sell2,000$61.841.68view
Werner Thomas ESVP, Finance & CFO 2014-12-15Sell10,000$60.8643.87view
Hoffman Richard JCVP, Controller & CAO 2014-12-02Sell21,850$60.3245.16view
SOKOLOV JACQUE JDirector 2014-11-28Sell7,547$60.3245.16view
Yoskowitz Marc JSVP, Strategy & Corporate Dev 2014-11-25Sell11,523$59.9346.1view
SMITH BRIAN JSVP and Special Counsel 2014-11-24Sell185,700$59.3147.63view
Meyers Kenneth FSVP, Chief Human Resources Ofr 2014-11-24Sell46,250$59.6646.77view
Bedward RoyceSVP, General Counsel and Sec'y 2014-11-20Sell2,333$58.6749.24view

Press Releases about HSP :

    Quarterly/Annual Reports about HSP:

    News about HSP:

    Articles On GuruFocus.com
    Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
    Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
    Feeling Good With This Med Company Jan 20 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
    Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
    Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
    Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
    Five Companies Cut - Pzena Investment Management Update Nov 12 2013 
    John Rogers Comments on Hospira Inc. Jul 25 2013 


    More From Other Websites
    HOSPIRA INC Files SEC form 8-K, Other Events Feb 27 2015
    Increased Mergers and Acquistions Help, But Headwinds Persist Feb 27 2015
    Stock Goes Nuts As Akorn Cracks Q4 EPS, '15 Views Feb 26 2015
    FDA postpones key hearing on biosimilar copy of blockbuster drug Feb 26 2015
    [$$] Generic Copies of Remicade Go on Sale in Europe Feb 26 2015
    Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
    Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
    Hospira and Celltrion launch biosimilars Feb 24 2015
    Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog Feb 23 2015
    UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Hospira Inc. of Class Action... Feb 23 2015
    Peterson's top sectors Feb 23 2015
    Hot Dividend Stocks: Pfizer Pulls Back Into Buy Range Feb 19 2015
    The Medicines Co. Earnings Down Y/Y, Angiomax Sales Grow - Analyst Blog Feb 19 2015
    Inflectra™ (infliximab) patient registry reports interim results in the treatment of inflammatory... Feb 19 2015
    HOSPIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Feb 18 2015
    HOSPIRA INC Financials Feb 18 2015
    HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of the Hospira, Inc.... Feb 17 2015
    Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Feb 17 2015
    Pfizer NDA on Pain Management Candidate Accepted by FDA - Analyst Blog Feb 17 2015
    Investor Lawsuit Against Acquisition of Hospira, Inc. (HSP) Announced by Shareholders Foundation Feb 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK